Previous 10 | Next 10 |
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has launched B2B sales of the rare cannabinoid cannabicitran (“CBT”) into the health and wellness sector. According to...
CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCV Expands the Company’s rare cannabinoid product portfolio, which also includes cannabichromene (CBC) Strengthens leadership position in comm...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the development, manufacturing and commercialization of rare cannabinoids, has released a shareholder letter. The letter, from president and CEO Eric A. Adams, provided INM shareholders with a company update, including a look at key mileston...
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today issued the following letter from P...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and General Manager of BayMedica, Shane Johnson, and VP of Commercial Operations Chris Meiering will present at Tribe ...
VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, announces that InMed’s CEO Eric A...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until...
VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed sci...
VANCOUVER, British Columbia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today confirmed that, at its annual gene...
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercializa...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...